Physician

Joseph Kannarkatt, M.D.

According to 2025 Medicare claims, Joseph Kannarkatt, M.D. (NPI: 1124311956) practices hematology/oncology in the York-Hanover, PA market, with the plurality of this provider's patient population coming from York, PA. This provider's primary affiliated billing organization is CANCER CARE ASSOCIATES OF YORK, INC. (NPI: 1578587101; TIN: 232122436) and primary practice location at 17403-5049.

Kannarkatt's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 875 traditional Medicare patients, billed 145,386 HCPCS/CPT codes, and received $3,242,119 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,156 prescription claims across 244 beneficiaries totaling $813,556 in drug costs, led by Lenalidomide (Lenalidomide). 2022 DME data shows 39 claims. Open Payments data shows 10 records totaling $39,327. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $378,734 to $813,556. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	36	176	$8,301
2018	688	146,785	$1,933,900
2019	870	238,493	$2,999,164
2020	847	205,079	$3,288,790
2021	864	135,839	$2,500,951
2022	814	140,388	$2,526,252
2023	910	156,453	$2,796,426
2024	875	145,386	$3,242,119

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	27	154	$378,734
2016	39	229	$502,835
2017	37	170	$373,589
2018	142	495	$199,508
2019	194	808	$317,420
2020	177	771	$691,656
2021	182	771	$716,001
2022	190	785	$539,664
2023	226	1,045	$627,837
2024	244	1,156	$813,556

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	42	119	$12,658
2019	N/R	57	$4,799
2020	N/R	15	$2,604
2021	N/R	19	$2,118
2022	N/R	39	$1,561
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	310	758	$130
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	410	812	$12
80053	Blood test, comprehensive group of blood chemicals	252	892	$10
36415	Insertion of needle into vein for collection of blood sample	416	1,482	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	371	1,307	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	13	322	$146,593
Eliquis	Apixaban	64	3,075	$60,196
Xarelto	Rivaroxaban	64	2,640	$48,201
Enoxaparin Sodium	Enoxaparin Sodium	31	650	$7,183
Exemestane	Exemestane	17	1,350	$3,902

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$5,508	OnMark, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$33,819	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph Kannarkatt, M.D.?

Tedicare shows public-source Medicare data for Joseph Kannarkatt, M.D. (NPI 1124311956), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph Kannarkatt, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph Kannarkatt, M.D.?

Joseph Kannarkatt, M.D. is linked to CANCER CARE ASSOCIATES OF YORK, INC. (billing NPI 1578587101) in the available physician profile data.

Does Joseph Kannarkatt, M.D. have Open Payments data?

Joseph Kannarkatt, M.D. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.